FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

l	OMB APPROVAL									
	OMB Number:	3235-0287								
l	Estimated average bu	rden								
ı	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>RIEFLIN WILLIAM JL</u>					<u>N</u> (2. Issuer Name and Ticker or Trading Symbol NGM BIOPHARMACEUTICALS INC NGM								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)	(First) (Middle) OYSTER POINT BOULEVARD					3. Date of Earliest Transaction (Month/Day/Year) 04/08/2019								X Officer (give title below) Other (special below) Executive Chairman					pecify	
(Street) SOUTH SAN FRANCISCO CA 94080				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(S	tate)	(Zip)												1 013011					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/Y				Execution Date,		3. 4. Securities Ac Transaction Code (Instr. 8) 5. 5.			Acquired (D) (Instr.	(A) or 3, 4 and	Beneficially Owned Following		ving	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
							Code	,	Amount	(A) or (D)	Price	Reported Transaction(s (Instr. 3 and 4					(Instr. 4)			
Common Stock 04/08/20			2019	19		С		56,668	A	(1)		2,769,168 I		I	See Footn		notes ⁽²⁾⁽³⁾			
		-	Γable I								posed of, , convertil				wned					
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any		on Date,	n Date, Transac Code (Ir				6. Date Exerc Expiration Da (Month/Day/Y		ate	7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amour or Number of Shares	er						
Series A Preferred Stock	(1)	04/08/2019			С			50,000	(1)		(1)	Common Stock	50,00	00	\$0.00		0		I	See Footnote ⁽³⁾
Series B Preferred Stock	(1)	04/08/2019			С			6,668	(1)		(1)	Common	6,66	8	\$0.00		0		I	See Footnote ⁽³⁾

Explanation of Responses:

- 1. Every two shares of Series A preferred stock and Series B preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering. These shares have no expiration date.
- 2. Mr. Rieflin early exercised certain shares of common stock, of which (i) 44,531 shares of common stock granted on January 27, 2016 remain unvested and (ii) 103,906 shares of common stock granted on January 20, 2017 remain unvested.
- 3. Shares held by the Rieflin Family Trust U/A 4/3/00.

Remarks:

/s/ William J. Rieflin

04/10/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.